Clinical Trials
82 trialsPANEL
University Hospital, Rouen
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Genmab
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
A Study of PF-06873600 in People With Cancer
Pfizer
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
PAVO
Tempus AI
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
AM-003
University of Virginia
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
START
Lyell Immunopharma, Inc.
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
C4431001
Pfizer
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
MasterKey-01
Black Diamond Therapeutics, Inc.
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Valerio Therapeutics
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
FPA150-001
Five Prime Therapeutics, Inc.
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Tango Therapeutics, Inc.
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
ORCHID-1
Medikine, Inc.
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
CytomX Therapeutics
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Fusion Pharmaceuticals Inc.
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
LODESTAR
pharmaand GmbH
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
ALpha-T
Hoffmann-La Roche
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
BRAVO
Tesaro, Inc.
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
Effect of PARP Inhibitors on Glomerular Filtration Rate
University of Pennsylvania
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
Novartis
F-Chem
Dr. Horst Schmidt Klinik GmbH
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
ExcellaBio LLC
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Syros Pharmaceuticals
A Safety Study of SGN-CD47M in Patients With Solid Tumors
Seagen Inc.
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
AIDS Malignancy Consortium
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
National Institutes of Health Clinical Center (CC)